FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Johnson Charles A 		2. Issuer Name and Ticker or Trading Symbol

INSPIRE PHARMACEUTICALS INC [ ISPH ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
EVP of R&D & Chief Med. Ofcr.
(Last)          (First)          (Middle)

C/O INSPIRE PHARMACEUTICALS, INC., 8081 ARCO CORPORATE DRIVE, SUITE 400 		3. Date of Earliest Transaction (MM/DD/YYYY)

5/13/2011
(Street)

RALEIGH, NC 27617
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)   $5.11   5/13/2011     D         250000      (1) 9/14/2017   Common Stock   250000     (1) 0   D    
Restricted Stock Unit     (2) 5/13/2011     D         27524      (2)   (2) Common Stock   27524     (2) 0   D    
Restricted Stock Unit     (2) 5/13/2011     D         150000      (2)   (2) Common Stock   150000     (2) 0   D    

Explanation of Responses:
( 1)  These stock options were cancelled in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of April 5, 2011, by and among, Merck & Co., Inc., Monarch Transaction Corp. and Inspire Pharmaceuticals, Inc. (the "Merger Agreement"). As the exercise price of the options was at or above $5.00, no cash payment was provided.
( 2)  Pursuant to the Merger Agreement, these restricted stock units ("RSUs"), whether or not vested, were fully vested immediately prior to and cancelled immediately following the acceptance time under the Merger Agreement in exchange for the right to receive cash payment for each such RSU of $5.00, net to the seller in cash, without interest and less any required withholding taxes.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Johnson Charles A
C/O INSPIRE PHARMACEUTICALS, INC.
8081 ARCO CORPORATE DRIVE, SUITE 400
RALEIGH, NC 27617

EVP of R&D & Chief Med. Ofcr.

Signatures
/s/ Edward P. Bromely III, Attorney-in-Fact 5/13/2011
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Inspire Pharmaceuticals, Inc. (MM) (NASDAQ:ISPH)
過去 株価チャート
から 5 2024 まで 6 2024 Inspire Pharmaceuticals, Inc. (MM)のチャートをもっと見るにはこちらをクリック
Inspire Pharmaceuticals, Inc. (MM) (NASDAQ:ISPH)
過去 株価チャート
から 6 2023 まで 6 2024 Inspire Pharmaceuticals, Inc. (MM)のチャートをもっと見るにはこちらをクリック